BioAccord System with ACQUITY Premier: Some Things Work Better Together
September 13, 2021|

Combining BioAccord, our most capable MS detection platform, with ACQUITY Premier UPLC, our highest performance LC system, to demonstrate superior performance.

LC-MS workflows for peptide MAM

Biopharma’s Future: Next-Generation LC-MS Workflows for Peptide MAM
March 18, 2021|
,

The development of biotherapeutics continues to accelerate with their potential to revolutionize disease treatment in areas not adequately addressed by small molecule therapeutics. However, the complexity of these macromolecules and the range of potential modification variants (attributes) creates an interesting analytical challenge for scientists tasked with their characterization and then with monitoring those attributes important…

Analytical Tools for Developing Biosimilars: Part 3, Glycosylation, Aggregation, and Charge Variants
January 13, 2017|

In biotherapeutics, the state of glycosylation has a direct and pronounced effect of the structure, stability, serum half-life, immunogeneicity and bioactivity of the molecule, and constitutes a critical quality attribute (CQA). In our study, characterizing and comparing the glycosylation profile of infliximab began by examining the glycosylation profiles from intact and reduced subunit mass data.

Analytical Tools for Developing Biosimilars: Part 2, Peptide Analysis
January 13, 2017|

Advancements in High-Resolution Analytics for Characterization of Innovator and Biosimilar Therapeutics Part 2: Peptide Analysis of Infliximab

How Analytical Technologies Support the Development of Biosimilar Drugs
January 12, 2017|

Advancements in High-Resolution Analytics for the Characterization of Innovator and Biosimilar Therapeutics As the pharmaceutical industry continues to evolve its focus from small-molecule drugs to balanced product portfolios that include protein therapeutics, analytical chemists are increasingly challenged to produce routine and automated characterization workflows that move innovator and biosimilar biopharmaceutical products forward through development and…

An Inflection Point for Biopharmaceutical Host Cell Protein Analysis
June 7, 2016|

Has LC-MS Become a Generally Accepted Tool for Complementing Immunoassay-based HCP Analysis? My colleague Catalin Doneanu and I just returned from Lisbon, Portugal, where we attended the BEBPA Conference on Host Cell Protein (HCP) analysis. Along with the other 120 attendees, we participated in open and thoughtful discussions on the best practices for HCP analysis…